• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Reporting practices of drug studies results have improved

19.01.2018/in News /by Evgenii Tkachenko

It has been reported that according to the Good Pharma Scorecard some big pharmaceutical companies comply with the legal requirements for disclosing results of the conducted clinical studies. However, the outcomes of many clinical trials still remain unreported.

Lately, a group of researchers has found out that many clinical reporting practices do not meet ethical and legal requirements in both academia and industry. An analysis of reporting practices by big companies between 2012 and 2014 was published in BMJ Open on the 5th of December 2017. The authors have compared the studies associated with medicines approved by FDA in 2012 and 2014.

“The good news is, for the trials that the companies conducted in patients to gain regulatory approval of their drug, [transparency levels] went up,” stated the paper co-author Jennifer Miller, a bioethicist at New York University and founder of Bioethics International, a non-profit organization dealing with ethical issues and the problem of transparency in pharmacy.

Jennifer Miller and her co-workers have created the Good Pharma Scorecard – a method of ranking of big pharmaceutical companies based on an investigation of reporting transparency of clinical trials linked to new drugs which were approved by FDA. In the latest analysis which was published in BMJ, they have investigated 505 studies linked to 19 new drugs which were sponsored by 11 big pharmaceutical companies and got FDA approval in 2014. The scientists had to look through 45 different databases including personal communications with pharmaceutical companies. They made their conclusions based on analysis of the facts whether reporting transparency complies with ethical standards (the study results should be available) and the legal standards of the 2007 FDA Amendments Act (the companies must report the outcomes of all controlled clinical studies, with the exception of phase I trials). The researchers have found out that only 67% of drug clinical investigations met FDAAA reporting requirements, and the outcomes of only 87% of clinical studies were open to the public. Though, by now these rates have improved reaching 71% and 96% respectively. However, according to Ulrich Dirnagl, a neurologist at Charité–Berlin University of Medicine, approximately 30% of all drugs approved in 2014 have been investigated in undisclosed phase II or III clinical studies which is a concerning fact.

Source: The scientist.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 2 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
New promising blood sugar pills for patients with type 2 diabetes GCP course for professionals
Scroll to top